Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Authors

Anne C. Moorman
Loralee B. Rupp, Henry Ford HealthFollow
Stuart C. Gordon, Henry Ford HealthFollow
Yuna ZhongFollow
Jian Xing
Mei Lu, Henry Ford HealthFollow
Joseph A. Boscarino
Mark A. Schmidt
Yihe G. Daida
Eyasu H. Teshale
Philip R. Spradling
Scott D. Holmberg

Recommended Citation

Infect Dis Clin North Am 2018; 32(2):253-268.

Document Type

Article

Publication Date

6-1-2018

Publication Title

Infectious disease clinics of North America

Abstract

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

Medical Subject Headings

Adult; Aged; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Observational Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Time Factors; Young Adult

PubMed ID

29778254

Volume

32

Issue

2

First Page

253

Last Page

268